Inno.N Signs Joint Development Agreement for Immunological Disease Treatments with Novacell

[Asia Economy Reporter Kim Ji-hee] inno.N (HK inno.N) announced on the 8th that it has signed an agreement to jointly develop autoimmune therapeutics with Novacell Technology, a peptide immunotherapy specialist company. Through this agreement, Novacell Technology will discover peptide candidate substances that resolve inflammation, and inno.N plans to conduct additional research and clinical trials on these substances with the goal of commercialization.

Peptides are substances typically composed of fewer than 50 amino acids linked together, making them smaller than proteins. Depending on the type, they play roles such as preventing inflammation, activating cells, and promoting cell generation within the body.

Inno.N plans to develop autoimmune disease therapeutics using a peptide candidate substance called the "3rd generation Peptoid (PEPTIROID)." Novacell is developing "Peptoids," peptides that induce the normal termination and recovery of inflammatory responses. Compared to previous generations, the 3rd generation Peptoids have enhanced efficacy by improving the activation ability and selectivity of the receptor (FPR2) important for resolving inflammation, increasing biological stability, and optimizing physical properties. At the same time, they feature the potential for expanded indications and administration routes.

To develop the 3rd generation Peptoids, Novacell is conducting structure-based joint research with the structural biology research team at POSTECH under the Ministry of Science and ICT's Kiuri project. They are also developing substances applying peptidomimetics (peptide mimetics) using artificial intelligence technology in collaboration with Hits Co., Ltd.

Go Dong-hyun, Executive Director of New Drug Research Institute at inno.N, said, "We are pleased to partner with Novacell, a leading company in peptide technology. We will strive to maximize the advantages of Peptoids to develop therapeutics that can be widely used for various inflammatory diseases." Lee Tae-hoon, CEO of Novacell, stated, "The inflammation resolution induction strategy possessed by Peptoids is attracting attention as a new treatment strategy for inflammatory diseases that complements existing shortcomings. We expect to create synergy in pipeline expansion based on the expertise of both companies."

This content was produced with the assistance of AI translation services.